Continuation of GLP-1 Receptor Agonist Use in Early Pregnancy Seems Safe WEDNESDAY, June 10, 2026 -- Continuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) into early pregnancy seems not to be associated with the risk for nonlive birth, abnormal fetal growth, or major congenital malformation (MCM), according to a study published online June 9 in the Annals of Internal Medicine
A trained clinician should demonstrate proper injection technique to minimize local irritation
Neither compound is approved by Health Canada for therapeutic use, and both are prohibited by the World Anti-Doping Agency
Minakova E, Lang J, Medel-Matus JS, Gould GG, Reynolds A, Shin D, Mazarati A, Sankar R
Heffernan M., Jiang W.J., Thorburn A.W., Ng F.M
Simple Daily Usage Designed for easy routine use with a serving size of 3 capsules per day, making it easy to stay consistent and maintain long-term wellness support